Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$27,000.00

Novel PROTAC-Based Therapeutic Strategy for Treating Drug-Resistant BRCA1/2-Mutant Cancers

EF 2024-25

Résumé
Breast and ovarian cancers associated with BRCA1/2 mutations present a significant clinical challenge due to their reliance on error-prone DNA repair mechanisms. While therapies such as PARP inhibitors (PARPi) have provided advancements, resistance to these treatments often develops, creating an urgent need for innovative strategies.This proposal focuses on targeting RNF8, an E3 ubiquitin ligase that plays a key role in DNA repair pathway selection and tumor progression in BRCA1/2-mutant cancers. Our preliminary studies indicate that degrading RNF8 disrupts both homologous recombination (HR) and non-homologous end joining (NHEJ), leading to synthetic lethality in BRCA1/2-mutant cancer cells. Furthermore, RNF8 degradation has shown efficacy in preclinical models, inhibiting tumor growth and overcoming resistance to existing therapies.To achieve this, we aim to develop a novel PROTAC-based therapeutic. PROTACs (Proteolysis-Targeting Chimeras) are cutting-edge compounds designed to induce the selective degradation of a target protein by bringing it into close proximity with an E3 ligase, leveraging the cell's ubiquitin-proteasome system for protein degradation. Our research plan involves screening and synthesizing RNF8-targeting PROTACs and evaluating their efficacy in BRCA1/2-mutant cancer cell lines and preclinical models.This approach not only addresses a critical unmet need in oncology but also leverages innovative technology to provide a potentially transformative therapeutic option. Success in this research could pave the way for new treatments for patients worldwide facing drug-resistant BRCA1/2-related cancers.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
529942
Name
Chiu Wing Chi
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Novel PROTAC-Based Therapeutic Strategy for Treating Drug-Resistant BRCA1/2-Mutant Cancers
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Brca1/2 Mutant Cancers; Dna Repair Pathways; Drug/Chemotherapy Resistance; E3 Ligase Binding; Oncology Innovation; Protac Technology; Rnf8 Ubiquitylation; Synthetic Lethality; Targeted Protein Degradation; Ubiquitin-Proteasome Degradation
Abstract
Breast and ovarian cancers associated with BRCA1/2 mutations present a significant clinical challenge due to their reliance on error-prone DNA repair mechanisms. While therapies such as PARP inhibitors (PARPi) have provided advancements, resistance to these treatments often develops, creating an urgent need for innovative strategies.This proposal focuses on targeting RNF8, an E3 ubiquitin ligase that plays a key role in DNA repair pathway selection and tumor progression in BRCA1/2-mutant cancers. Our preliminary studies indicate that degrading RNF8 disrupts both homologous recombination (HR) and non-homologous end joining (NHEJ), leading to synthetic lethality in BRCA1/2-mutant cancer cells. Furthermore, RNF8 degradation has shown efficacy in preclinical models, inhibiting tumor growth and overcoming resistance to existing therapies.To achieve this, we aim to develop a novel PROTAC-based therapeutic. PROTACs (Proteolysis-Targeting Chimeras) are cutting-edge compounds designed to induce the selective degradation of a target protein by bringing it into close proximity with an E3 ligase, leveraging the cell's ubiquitin-proteasome system for protein degradation. Our research plan involves screening and synthesizing RNF8-targeting PROTACs and evaluating their efficacy in BRCA1/2-mutant cancer cell lines and preclinical models.This approach not only addresses a critical unmet need in oncology but also leverages innovative technology to provide a potentially transformative therapeutic option. Success in this research could pave the way for new treatments for patients worldwide facing drug-resistant BRCA1/2-related cancers.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chiu, Wing Chi
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~